Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin Clear all
Completed Not applicable Interventional

Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)

NCT00130481
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Atorvastatin 20 mg daily for 3 months
Drug
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ARREST PAD (Peripheral Arterial Disease)

NCT00153166
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions
atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691
View directory record Official record
Conditions
Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
181
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2007 · Synced Oct 16, 2026, 9:29 PM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589
View directory record Official record
Conditions
Healthy Controls
Interventions
Atorvastatin, Pneumovax 23, Placebo (lactose pill)
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

NCT01112670
View directory record Official record
Conditions
Healthy
Interventions
Sitagliptin, atorvastatin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

NCT01263938
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Atorvastatin

NCT02749578
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 3 Interventional

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

NCT00214630
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
rosuvastatin calcium, atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
52
States / cities
San Diego, California • Torrance, California • Bridgeport, Connecticut + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 3 Interventional

The Effects of Atorvastatin in Patients With Atherosclerosis

NCT00115817
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 16, 2026, 9:29 PM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
View directory record Official record
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Not applicable Interventional Results available

Statin Therapy to Improve Atherosclerosis in HIV Patients

NCT00965185
View directory record Official record
Conditions
Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Not applicable Interventional

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

NCT00137176
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2009 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Actual Use Trial of Atorvastatin Calcium 10 mg

NCT01964326
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin calcium 10 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
37
States / cities
Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 16, 2026, 9:29 PM EDT
Terminated Phase 2Phase 3 Interventional

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

NCT00622089
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Atorvastatin for Orthopedic Surgery Patients

NCT02197065
View directory record Official record
Conditions
Hip Fracture, Myocardial Ischemia, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

NCT04747847
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Atorvastatin and anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Year to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 16, 2026, 9:29 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

NCT02227784
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evacetrapib, Atorvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
61
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 16, 2026, 9:29 PM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882
View directory record Official record
Conditions
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
Interventions
Atorvastatin
Drug
Lead sponsor
Joaquina Baranda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 16, 2026, 9:29 PM EDT
Completed No phase listed Observational

Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor

NCT01078285
View directory record Official record
Conditions
Medication Non-Adherence
Interventions
No Patient Counseling, Adherence Counseling
Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 16, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

NCT01499771
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 66 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 16, 2026, 9:29 PM EDT